On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Anne Floquet

ResearcherPublications, citations & collaboration network

Anne Floquet is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Anne Floquet have?

ScholarIQindexed works

Anne Floquet has 498 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Anne Floquet have?

ScholarIQcitation count

Anne Floquet has 18,656 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Anne Floquet?

ScholarIQh-index

Anne Floquet has an h-index of 53 in OpenAlex.

What is the i10-index of Anne Floquet?

ScholarIQi10-index

Anne Floquet has an i10-index of 119 in OpenAlex.

What is the ORCID of Anne Floquet?

ScholarIQorcid

The ORCID for Anne Floquet is on the source record.

What is the OpenAlex record for Anne Floquet?

ScholarIQopenalex

The OpenAlex for Anne Floquet is on the source record.

What are the most-cited papers on Anne Floquet?

ScholarIQmost cited works
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro
New England Journal of Medicine. 20182,881 CitationsOPEN ACCESS
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, Val Gebski, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata, Michael Friedländer, Nicoletta Colombo, Philipp Harter, Keiichi Fujiwara, Isabelle Ray‐Coquard, Susana Banerjee, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Patricia Pautier, Jacob Korach, Tomasz Huzarski, Tomasz Byrski, Patricia Pautier, Michael Friedländer, Philipp Harter, Nicoletta Colombo, Sandro Pignata, Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan A. Davidson
The Lancet Oncology. 20171,881 Citations
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Léary, Robert W. Holloway, Margarita Amenedo, Peter C.C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Jesús García-Donás, Elizabeth M. Swisher, Anne Floquet, Gottfried E. Konecny, Iain A. McNeish, Clare L. Scott, T. Cameron, Lara Maloney, Jeff Isaacson, Sandra Goble, Caroline A. Grace, Thomas C. Harding, Mitch Raponi, James Sun, Kevin Lin, Heidi Giordano, Jonathan A. Ledermann, Martin Buck, Andrew Dean, Michael Friedländer, Jeffrey C. Goh, Paul R. Harnett, Ganessan Kichenadasse, Clare L. Scott, Hannelore Denys, Luc Dirix, Ignace Vergote, Laurie Elit, Prafull Ghatage, Amit M. Oza, Marie Plante, Diane Provencher, Johanne I. Weberpals, Stephen Welch, Anne Floquet, Laurence Gladieff, Florence Joly, Alexandra Léary, Alain Lortholary, Jean‐Pierre Lotz, Jacques Médioni, Olivier Trédan, Benoît You, Ayşe Balat, Claudia Hänle, Petra Krabisch, Tanja Neunhöffer, Martin Pölcher, Pauline Wimberger, A Amit, Svetlana Kovel, Michelle Leviov, Tamar Safra, Ronnie Shapira‐Frommer, Salomon M. Stemmer, Alessandra Bologna, Nicoletta Colombo, Domenica Lorusso, Sandro Pignata, Roberto Sabbatini, Giovanni Scambia, Stefano Tamberi, Claudio Zamagni, Peter C.C. Fong, Anne O’Donnell, Margarita Amenedo, A. Casado Herráez, Jesús García-Donás, E.M. Guerra, Ana Oaknin, Isabel Palacio, Ignacio Romero, A Sanchez, Susana Banerjee, Andrew R. Clamp, Yvette Drew, Hani Gabra, D Jackson, JA Ledermann, Iain A. McNeish, C. A. Parkinson, Melanie Powell, Carol Aghajanian
The Lancet. 20171,721 CitationsOPEN ACCESS
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher, Kevin Lin, Amit M. Oza, Clare L. Scott, Heidi Giordano, James Sun, Gottfried E. Konecny, Robert L. Coleman, Anna V. Tinker, David M. O’Malley, Rebecca Kristeleit, Ling Ma, Katherine M. Bell‐McGuinn, James D. Brenton, Janiel M. Cragun, Ana Oaknin, Isabelle Ray‐Coquard, Maria I. Harrell, Elaina Mann, Scott H. Kaufmann, Anne Floquet, Alexandra Léary, Thomas C. Harding, Sandra Goble, Lara Maloney, Jeff Isaacson, Andrew R. Allen, Lindsey Rolfe, Roman Yelensky, Mitch Raponi, Iain A. McNeish
The Lancet Oncology. 20161,209 CitationsOPEN ACCESS
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, John McNamara, Elizabeth Lowe, Mei-Lin Ah-See, Kathleen N. Moore, on behalf of the SOLO1 Investigators
Journal of Clinical Oncology. 2022488 CitationsOPEN ACCESS

Related on ScholarIQ

470M+ articles · free account